Upadhyay, Amit A. http://orcid.org/0000-0002-0952-4164
Viox, Elise G.
Hoang, Timothy N. http://orcid.org/0000-0002-7781-1130
Boddapati, Arun K.
Pino, Maria
Lee, Michelle Y.-H. http://orcid.org/0000-0002-5722-1109
Corry, Jacqueline http://orcid.org/0000-0003-1942-1529
Strongin, Zachary
Cowan, David A.
Beagle, Elizabeth N.
Horton, Tristan R.
Hamilton, Sydney
Aoued, Hadj
Harper, Justin L. http://orcid.org/0000-0002-6948-3501
Edwards, Christopher T. http://orcid.org/0000-0002-6552-4097
Nguyen, Kevin
Pellegrini, Kathryn L.
Tharp, Gregory K. http://orcid.org/0000-0003-3075-755X
Piantadosi, Anne http://orcid.org/0000-0002-5942-1534
Levit, Rebecca D. http://orcid.org/0000-0001-5405-8716
Amara, Rama R. http://orcid.org/0000-0002-6309-6797
Barratt-Boyes, Simon M.
Ribeiro, Susan P.
Sekaly, Rafick P. http://orcid.org/0000-0002-7816-4828
Vanderford, Thomas H.
Schinazi, Raymond F. http://orcid.org/0000-0002-6688-3614
Paiardini, Mirko http://orcid.org/0000-0002-7276-3600
Bosinger, Steven E. http://orcid.org/0000-0002-2116-5061
Article History
Received: 4 October 2021
Accepted: 16 March 2023
First Online: 6 April 2023
Competing interests
: R.F.S. has served in the past as an unpaid consultant for Eli Lilly whose drugs are being evaluated in the research described in this paper, and owns shares in Eli Lilly. He also receives royalties from the sales of Baricitinib for COVID-19 in the US and Mexico. The terms of this arrangement have been reviewed and approved by Emory University in accordance with its conflict of interest policies. All other authors do not have any conflicts to declare.